TY - JOUR
T1 - Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555
AU - Upton, R.
AU - Widdowson, P. S.
AU - Ishii, S.
AU - Tanaka, H.
AU - Williams, G.
PY - 1998
Y1 - 1998
N2 - 1. We examined the effect of chronic (21 days) oral treatment with the thiazolidinedione, MCC-555 ((±)-5-[{6-(2-fluorbenzyl)-oxy-2-naphy}methyl]-2,4-thiazolidinedione) on metabolic status and insulin sensitivity in obese (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats which display an impaired glucose tolerance (IGT) or overt diabetic symptoms, respectively. 2. MCC-555 treatment to obese Zucker rats (10 and 30 mg kg-1) and diabetic ZDF rats (10 mg kg-1) reduced non-esterified fatty acid concentrations in both rat strains and reduced plasma glucose and triglyceride concentrations in the obese Zucker rats. Liver glycogen concentrations were significantly increased by chronic MCC-555 treatment in both obese Zucker rats (30 mg kg-1 day-1) and diabetic ZDF rats (10 mg kg-1 day-1), as compared with vehicle-treated lean and obese rats and there was a significant increase in hepatic glycogen synthase activity in MCC-555-treated diabetic ZDF rats as compared to vehicle-treated controls. 3. During a euglycaemic hyperinsulinaemic clamp, MCC-555-treated obese Zucker rats and diabetic ZDF rats required significantly higher glucose infusion rates to maintain stable glucose concentrations (2.01 ± 0.19 mg min-1 and 6.42 ± 1.03 mg min-1, respectively) than vehicle-treated obese controls (0.71 ± 0.17 mg min-1 and 2.09 ± 0.71 mg min-1; P < 0.05), demonstrating improved insulin sensitivity in both Zucker and ZDF rats. MCC-555 treatment also enhanced insulin-induced suppression of hepatic glucose production in ZDF rats as measured using infusions of [6-3H]-glucose under clamp conditions. 4. In conclusion, we have demonstrated that MCC-555 improves metabolic status and insulin sensitivity in obese Zucker and diabetic ZDF rats. MCC-555 may prove a useful compound for alleviating the metabolic disturbances and IGT associated with insulin resistance in man.
AB - 1. We examined the effect of chronic (21 days) oral treatment with the thiazolidinedione, MCC-555 ((±)-5-[{6-(2-fluorbenzyl)-oxy-2-naphy}methyl]-2,4-thiazolidinedione) on metabolic status and insulin sensitivity in obese (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats which display an impaired glucose tolerance (IGT) or overt diabetic symptoms, respectively. 2. MCC-555 treatment to obese Zucker rats (10 and 30 mg kg-1) and diabetic ZDF rats (10 mg kg-1) reduced non-esterified fatty acid concentrations in both rat strains and reduced plasma glucose and triglyceride concentrations in the obese Zucker rats. Liver glycogen concentrations were significantly increased by chronic MCC-555 treatment in both obese Zucker rats (30 mg kg-1 day-1) and diabetic ZDF rats (10 mg kg-1 day-1), as compared with vehicle-treated lean and obese rats and there was a significant increase in hepatic glycogen synthase activity in MCC-555-treated diabetic ZDF rats as compared to vehicle-treated controls. 3. During a euglycaemic hyperinsulinaemic clamp, MCC-555-treated obese Zucker rats and diabetic ZDF rats required significantly higher glucose infusion rates to maintain stable glucose concentrations (2.01 ± 0.19 mg min-1 and 6.42 ± 1.03 mg min-1, respectively) than vehicle-treated obese controls (0.71 ± 0.17 mg min-1 and 2.09 ± 0.71 mg min-1; P < 0.05), demonstrating improved insulin sensitivity in both Zucker and ZDF rats. MCC-555 treatment also enhanced insulin-induced suppression of hepatic glucose production in ZDF rats as measured using infusions of [6-3H]-glucose under clamp conditions. 4. In conclusion, we have demonstrated that MCC-555 improves metabolic status and insulin sensitivity in obese Zucker and diabetic ZDF rats. MCC-555 may prove a useful compound for alleviating the metabolic disturbances and IGT associated with insulin resistance in man.
KW - Diabetes
KW - MCC-555
KW - Metabolism
KW - Obese (fa/fa) Zucker rats
KW - Thiazolidinedione
UR - http://www.scopus.com/inward/record.url?scp=0032406145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032406145&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0702245
DO - 10.1038/sj.bjp.0702245
M3 - Article
C2 - 9886762
AN - SCOPUS:0032406145
SN - 0007-1188
VL - 125
SP - 1708
EP - 1714
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 8
ER -